查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947955

地理萎缩症治疗市场：依药物类别、给药途径、最终用户、通路和疾病阶段划分，全球预测，2026-2032年

Geographic Atrophy Drugs Market by Drug Class, Delivery Method, End User, Distribution Channel, Disease Stage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，地理萎缩治疗市场价值将达到 2.7924 亿美元，到 2026 年将成长至 3.3727 亿美元，到 2032 年将达到 11.8049 亿美元，复合年增长率为 22.86%。

关键市场统计数据
基准年 2025 2.7924亿美元
预计年份：2026年 3.3727亿美元
预测年份 2032 11.8049亿美元
复合年增长率 (%) 22.86%

策略性介绍概述了推动下一代地理萎缩治疗创新发展的科学、临床和营运背景。

地理萎缩症的治疗需求已从数十年的未满足状态迅速发展成为一个快速演变的治疗领域，这得益于新的生物学见解、先进的影像学终点指标以及不断扩展的临床试验体系。本导言总结了干预措施的临床原理，概述了目前正在积极研究的关键治疗方法，并提出了支付方、临床领导者和行业战略家在新的治疗方法从临床试验过渡到常规临床实践过程中必须考虑的战略问题。

生物学、监管先例和递送技术的突破如何汇聚一堂，重新定义治疗地图状萎缩的临床路径和商业策略

地理萎缩的治疗格局正在经历一场变革性的转变，这主要得益于科学技术的进步、监管先例的製定以及治疗标准的改变。补体通路调节提供了首个临床概念验证，刺激了投资并扩大了研究方向，涵盖了基因疗法、缓释平台和辅助神经保护策略。这些科学进展正在重塑临床试验终点，并鼓励更广泛地采用多模态影像生物标记和患者报告结局，以捕捉病灶指标之外的更有意义的疗效。

评估2025年关税变化对眼科药物采购、本地化生产和分销韧性的供应链压力和战略要务

2025年关税的实施和贸易政策的调整，为包括地理萎缩治疗药物在内的全球眼科治疗供应链带来了额外的营运复杂性。製造商和供应商在跨国采购时，某些活性药物成分、特殊包装和眼科给药装置的投入成本增加，迫使一些企业重新评估其製造地并调整供应商多元化策略。为此，一些研发企业开始从地理位置较近的供应商采购，并探索建立本地生产伙伴关係，以降低关税波动带来的风险。

基于详细细分的洞察，整合治疗方法、给药途径、临床环境和患者群体，为地理萎缩的临床和商业策略提供资讯。

地理萎缩症治疗药物的細項分析，揭示了不同产品类型、给药途径、临床环境、商业管道、疾病阶段和患者群体在临床应用案例、研发路径和相关人员优先事项方面的差异。依药物类别划分，涵盖生物製药、基因疗法和小分子药物，其中生物製药类别又细分为融合蛋白和单株抗体。每个类别都有其独特的研发时间表、生产复杂性和监管考量，这些都会影响临床开发和商业化策略。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和进入途径将影响监管方法、临床应用和供应策略。

区域趋势正在影响地理萎缩治疗的监管预期、治疗模式和患者就医途径。在美洲，监管机构对能够延缓疾病进展和保留功能的证据持开放态度，医疗服务体係也在调整以适应重复玻璃体内注射和新兴长效给药平台的营运需求。此外，该地区多元化的支付方格局也要求制定个人化的医疗技术评估策略和真实世界证据，以支持医保覆盖决策。

策略性企业行动与伙伴关係模式，旨在加速地图状萎缩症治疗领域的治疗创新、优化给药方式和产生实证医学证据

众多生物製药公司、专业医疗设备开发商和学术联盟正在为地理萎缩症的治疗创造一个既竞争又合作的环境。现有生物技术公司开发的补体通路抑制剂已获得临床概念验证，推动了生物製药和基因疗法领域的创新浪潮。同时，大型製药企业和专业医疗设备公司正在投资建立可扩展的生产能力和给药平台，以支援更广泛的临床应用。

产业领导者提出的可操作优先事项整合了证据产生、交付创新、供应链韧性和支付方合作，以加速临床应用。

产业领导者应优先考虑整合临床证据产生、交付创新和供应链韧性的整合策略，以加速患者获得治疗，同时降低营运风险。首先，应将临床开发项目与可操作的疗效指标和真实世界数据收集相结合，确保疗效讯号转化为对支付方有价值的证据。对註册登记和核准后监测的投入有助于进行长期价值对话，并将其纳入临床指南。同时，应优先考虑以患者为中心的交付解决方案，例如长效植入和微粒技术，以减轻治疗负担，并在不同的医疗环境中检验其安全性，从而促进其在门诊中心、医院和眼科诊所的推广应用。

采用透明的三角研究途径，结合文献综述、监管审查、专家访谈和临床路径分析，以产生可操作的见解。

本研究综合分析采用三角测量法，结合系统性文献回顾、监管文件分析、专家访谈和临床路径图谱，建构了地理萎缩治疗领域的整体情况。文献回顾涵盖了同行评审的临床研究、视网膜生物学转化研究以及关于视网膜成像和功能性结局指标的文章。监管材料和标籤指南的分析旨在确定核准视网膜疾病核准的证据要件和领先。

综述强调，证据的一致性、治疗方法的可行性和操作准备将决定地理萎缩治疗的长期临床和医学影响。

总之，地图状萎缩症的治疗领域正处于一个转折点，科学检验、监管先例和给药创新相结合，为改变许多患者的疾病自然进程创造了切实的机会。补体标靶治疗、新兴的基因疗法和缓释给药平台的整合，为延缓疾病进展和保护视力提供了多种途径，但其在临床实践中的广泛应用，取决于能否提供充分的证据证明其具有显着的功能获益、可控的安全性以及可行的给药模式。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的地理萎缩症治疗市场

  • 生物製药
    • 融合蛋白
    • 单株抗体
  • 基因治疗
  • 低分子化合物

9. 依给药途径分類的地理萎缩症治疗市场

  • 玻璃体内注射
  • 缓释系统
    • 植入
    • 细颗粒物
  • 外用製剂

第十章 以最终使用者分類的地理萎缩症治疗市场

  • 门诊手术中心
  • 医院
    • 二级护理
    • 三级医疗
  • 眼科诊所

第十一章 地理萎缩症治疗市场（依分销管道划分）

  • 在线的
  • 离线

第十二章：依疾病阶段分類的地图状萎缩症治疗市场

  • 晚期
  • 最初的
  • 过渡时期

第十三章 区域性地图状萎缩症治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 地理萎缩症治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国地理萎缩症治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国地理萎缩症治疗市场

17. 中国：地理萎缩症治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Graybug Vision, Inc.
  • Ionis Pharmaceuticals, Inc.
  • IVERIC bio, Inc.
  • Kodiak Sciences Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
Product Code: MRR-4F7A6D4FB6A5

The Geographic Atrophy Drugs Market was valued at USD 279.24 million in 2025 and is projected to grow to USD 337.27 million in 2026, with a CAGR of 22.86%, reaching USD 1,180.49 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 279.24 million
Estimated Year [2026] USD 337.27 million
Forecast Year [2032] USD 1,180.49 million
CAGR (%) 22.86%

A strategic introduction that frames the scientific, clinical, and operational context driving the next wave of Geographic Atrophy therapeutic innovation

Geographic atrophy is emerging from decades of unmet need into a rapidly evolving therapeutic domain shaped by novel biology, refined imaging endpoints, and an expanding clinical trial ecosystem. This introduction synthesizes the clinical rationale for intervention, summarizes the primary therapeutic modalities under active investigation, and frames the strategic considerations that payers, clinical leaders, and industry strategists must address as new interventions transition from trials into routine care.

Advances in understanding complement pathway dysregulation, neuroinflammation, and retinal cell survival mechanisms have converged with improved retinal imaging and functional outcome measures to create a viable pathway for therapeutic innovation. Translational work has accelerated candidate selection, while adaptive trial designs and real-world data collection are enabling earlier signals of durability and safety. At the same time, stakeholders face practical challenges around treatment delivery, patient selection, and long-term monitoring that will shape adoption and care pathways.

This section sets the foundation for deeper analysis by highlighting the interplay between scientific progress and operational considerations. It emphasizes how clinicians, health systems, and developers can align on evidence generation, post-approval surveillance, and care models that preserve sight while ensuring that new therapies integrate into existing ophthalmic practice efficiently and equitably.

How breakthroughs in biology, regulatory precedent, and delivery technologies are converging to redefine clinical pathways and commercial strategies for Geographic Atrophy therapies

The landscape for geographic atrophy therapeutics is undergoing transformative shifts driven by converging scientific advances, regulatory precedent, and changing standards of care. Complement pathway modulation has provided the first clinical proof of concept, catalyzing investment and a broadened research focus that now includes gene-based approaches, sustained-release platforms, and adjunct neuroprotective strategies. These scientific developments are reshaping clinical trial endpoints, prompting wider adoption of multi-modal imaging biomarkers and patient-reported outcomes to capture meaningful benefits beyond lesion metrics.

Concurrently, regulatory agencies have signaled pathways for expedited review when compelling evidence of slowed progression or preserved function emerges, which encourages companies to pursue robust safety monitoring and longer-term durability endpoints. Health systems and clinicians are adapting workflows to support recurring intravitreal administration and to integrate new sustained-delivery technologies that aim to reduce treatment burden. Payers are increasingly scrutinizing real-world effectiveness and value over time, prompting manufacturers to design outcomes-based agreements and to collect longitudinal evidence that aligns with payor priorities.

Taken together, these shifts create a dynamic environment in which scientific innovation, regulatory clarity, and care-delivery optimization interact. Stakeholders that anticipate changes in reimbursement, invest in patient-centric outcome measures, and develop delivery solutions that mitigate treatment burden will be better positioned to translate scientific promise into sustainable clinical impact.

Assessment of how 2025 tariff shifts created supply chain pressures and strategic imperatives for sourcing, manufacturing localization, and distribution resilience in ophthalmic therapeutics

The imposition of tariffs and trade policy adjustments in 2025 introduced additional operational complexities for global supply chains supporting ophthalmic therapeutics, including those for geographic atrophy. Manufacturers and suppliers experienced increased input costs for certain active pharmaceutical ingredients, specialty packaging, and ophthalmic delivery devices when components crossed tariffed borders, prompting some organizations to reassess manufacturing footprints and supplier diversification strategies. In response, several developers initiated sourcing shifts toward geographically proximate suppliers and examined localized manufacturing partnerships to reduce exposure to tariff volatility.

These developments also influenced logistics planning, with firms prioritizing inventory buffers for clinically critical components and accelerating qualification of secondary suppliers to maintain continuity of clinical trial supply and post-approval product availability. Health systems that rely on cross-border procurement for implants, microparticle carriers, and single-use procedural devices encountered variations in procurement timelines and unit costs, which required tighter coordination between supply chain, pharmacy, and clinical teams. Additionally, manufacturers working with global distribution networks adjusted contractual terms to allocate tariff-related risks and to ensure pricing transparency across regions.

Overall, the cumulative impact of tariff changes underscored the importance of resilient supply chain design and flexible commercial strategies. Organizations that proactively evaluated supplier risk, invested in regional manufacturing resilience, and built adaptable distribution agreements were better able to maintain clinical program continuity and respond to shifting procurement dynamics across regions.

Deep segmentation-driven insights that align therapeutic modality, delivery approach, care setting, and patient demographics to inform clinical and commercial strategy for Geographic Atrophy

A segmented view of geographic atrophy therapeutics clarifies clinical use cases, development pathways, and stakeholder priorities across product types, delivery approaches, care settings, commercial channels, disease stage, and patient demographics. Within drug class, the landscape encompasses Biologics, Gene Therapy, and Small Molecules, with the Biologics category further differentiated into Fusion Proteins and Monoclonal Antibodies; each class presents distinct R&D timelines, manufacturing complexities, and regulatory considerations that influence clinical development and commercialization strategies.

Delivery method plays a pivotal role in patient acceptance and clinical workflow, ranging from Intravitreal Injection to Sustained Release Systems and Topical Formulation, with Sustained Release Systems further divided into Implants and Microparticles; these options affect dosing frequency, procedural requirements, and long-term safety monitoring. End user segmentation highlights where interventions are delivered and managed, spanning Ambulatory Surgical Centers, Hospitals, and Ophthalmology Clinics, while recognizing that Hospitals may operate at different levels of care such as Secondary Care and Tertiary Care, each with unique procedural capacities and referral patterns.

Distribution channel distinctions between Hospital Pharmacy, Retail Pharmacy, and Specialty Pharmacy shape reimbursement touchpoints and patient access pathways. Disease stage segmentation across Advanced Stage, Early Stage, and Intermediate Stage guides trial design and therapeutic intent, from slowing expansion of atrophy to preserving function earlier in the disease course. Patient age group stratification into 50 to 64, 65 to 74, 75 to 84, and 85 and above informs adherence dynamics, comorbidity management, and communication strategies for shared decision-making. By integrating these segment lenses, stakeholders can tailor clinical development, commercialization, and care delivery plans that align therapeutic attributes with the needs of patients and providers.

Regional dynamics and access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory approaches, clinical adoption, and supply strategies

Regional dynamics shape regulatory expectations, care delivery models, and patient access pathways for geographic atrophy interventions. In the Americas, regulatory authorities have been receptive to evidence demonstrating slowed disease progression and functional preservation, and health-care delivery systems are adapting to the operational demands of recurring intravitreal administration and newer sustained-delivery platforms. This region also presents diverse payer landscapes that require tailored health technology assessment strategies and real-world evidence to support coverage decisions.

Europe, Middle East & Africa present heterogeneous regulatory frameworks and reimbursement environments that demand localized evidence packages and engagement strategies with national health authorities and payer bodies. Clinicians in these regions increasingly rely on cross-border collaborative networks and registries to aggregate longitudinal outcomes, while differences in care infrastructure influence the adoption pace of advanced delivery systems and gene-based approaches. In several sub-regions, access constraints and procurement processes necessitate focused demonstrations of cost-effectiveness and implementation feasibility for widespread adoption.

Asia-Pacific encompasses a mix of established markets with advanced retinal care centers and emerging markets where diagnostic capacity and specialized ophthalmology services are expanding rapidly. Regulatory pathways in Asia-Pacific vary, with some agencies offering expedited review processes for therapies addressing significant unmet needs, while supply chain and localization considerations influence commercialization strategies. Across regions, aligning clinical development with local care models, reimbursement criteria, and manufacturing logistics remains essential to ensuring equitable access and sustained clinical impact.

Strategic company behaviors and partnership models that are accelerating therapeutic innovation, delivery optimization, and evidence generation for Geographic Atrophy interventions

A diverse set of biopharma companies, specialty device developers, and academic consortia are shaping the competitive and collaborative environment around geographic atrophy therapies. Established biotech firms that advanced complement pathway inhibitors have demonstrated clinical proof of concept and catalyzed a wave of innovation across both biologic and gene-based modalities. At the same time, larger pharmaceutical organizations and specialty device companies are investing in scalable manufacturing capabilities and delivery platforms to support broader clinical adoption.

Across the ecosystem, strategic partnerships between companies with complementary capabilities-such as those combining gene therapy know-how with ophthalmic delivery expertise-are accelerating development of next-generation interventions. Contract manufacturing organizations and specialty pharmacies have also become critical partners, providing the infrastructure for complex biologic production, cold-chain distribution, and patient support programs that are essential for outpatient administration and adherence. Furthermore, academic centers and cooperative research networks play a central role in validating novel endpoints and generating real-world evidence that informs regulatory and reimbursement discussions.

Companies that invest in differentiated delivery solutions, robust safety monitoring frameworks, and data generation plans that align with payer priorities will reinforce clinical credibility and commercial viability. Strategic licensing and co-development arrangements can bridge capability gaps and de-risk late-stage development while enabling broader geographic reach through localized manufacturing and distribution partnerships.

Actionable priorities for industry leaders to align evidence generation, delivery innovation, supply chain resilience, and payer engagement to accelerate clinical adoption

Industry leaders should prioritize an integrated strategy that balances clinical evidence generation, delivery innovation, and supply chain resilience to accelerate patient access while mitigating operational risks. Start by aligning clinical development programs with pragmatic outcome measures and real-world data collection so that efficacy signals translate into payer-relevant evidence; investing in registries and post-approval surveillance will support long-term value conversations and clinical guideline integration. Simultaneously, prioritize patient-centered delivery solutions that reduce treatment burden-such as sustained-release implants and microparticle technologies-while validating safety in diverse care settings to facilitate adoption across ambulatory centers, hospitals, and ophthalmology clinics.

Strengthening supply chain resilience is equally important. Evaluate supplier concentration risks, qualify secondary manufacturing partners, and consider regional manufacturing or packaging options to reduce exposure to policy-driven cost fluctuations and trade disruptions. From a commercial perspective, develop flexible contracting models that can accommodate value-based components and outcomes-linked agreements, and partner with specialty pharmacies and hospital pharmacy systems to streamline access pathways. Finally, cultivate multi-stakeholder engagement with clinicians, payers, and patient advocacy groups to co-create education, adherence programs, and care pathways that optimize treatment uptake and persistence.

By executing on these priorities, organizations can translate scientific advances into practical, equitable care solutions while safeguarding operational continuity and demonstrating sustainable value to health systems and patients.

A transparent, triangulated research approach combining literature synthesis, regulatory review, expert clinician interviews, and clinical pathway analysis to produce actionable insights

This research synthesis draws on a triangulated methodology combining systematic literature review, regulatory document analysis, expert interviews, and clinical pathway mapping to construct a comprehensive picture of the geographic atrophy therapeutic landscape. The literature review targeted peer-reviewed clinical studies, translational research on retinal biology, and publications describing retinal imaging and functional outcome measures. Regulatory materials and labeling guidance were analyzed to identify evidentiary expectations and precedent pathways for accelerated or conditional approval in degenerative retinal conditions.

To complement secondary sources, semi-structured interviews were conducted with retina specialists, clinical trial investigators, health-system pharmacy leaders, and supply chain executives to capture frontline operational realities and adoption barriers. These conversations informed the evaluation of delivery modalities, procedural workflows, and inpatient versus outpatient care models. Additionally, a review of clinical trial registries and company disclosures helped map therapeutic classes in active development, while public post-marketing safety communications and registry reports were used to assess real-world safety monitoring practices.

Findings were synthesized through iterative triangulation to reconcile clinical, regulatory, and operational perspectives. Throughout the process, emphasis was placed on transparency of evidence sources, validation against expert input, and the generation of actionable insights that are directly relevant to clinical decision-makers, commercial strategists, and policy professionals.

Concluding synthesis highlighting how evidence alignment, delivery feasibility, and operational readiness will determine the long-term clinical and care impact of Geographic Atrophy therapies

In conclusion, the field of geographic atrophy therapeutics is at an inflection point where scientific validation, regulatory precedent, and delivery innovation are creating tangible opportunities to alter the natural history of disease for many patients. The integration of complement-directed therapies, emerging gene-based approaches, and sustained-release delivery platforms offers multiple pathways to reduce progression and preserve vision, but real-world adoption will depend on evidence that demonstrates meaningful functional benefit, manageable safety profiles, and feasible care delivery models.

Operational readiness-spanning supply chain resilience, provider training, and coordinated reimbursement strategies-will determine how quickly new therapies become widely available. Stakeholders that align clinical development with payer-relevant outcomes, optimize delivery to minimize treatment burden, and invest in robust long-term monitoring will be positioned to deliver the greatest clinical and societal benefit. Ultimately, translating scientific promise into sustained improvements in patient outcomes requires collaboration across industry, clinicians, payers, and patient communities to ensure therapies are safe, effective, and accessible.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Geographic Atrophy Drugs Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Fusion Proteins
    • 8.1.2. Monoclonal Antibodies
  • 8.2. Gene Therapy
  • 8.3. Small Molecules

9. Geographic Atrophy Drugs Market, by Delivery Method

  • 9.1. Intravitreal Injection
  • 9.2. Sustained Release Systems
    • 9.2.1. Implants
    • 9.2.2. Microparticles
  • 9.3. Topical Formulation

10. Geographic Atrophy Drugs Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
    • 10.2.1. Secondary Care
    • 10.2.2. Tertiary Care
  • 10.3. Ophthalmology Clinics

11. Geographic Atrophy Drugs Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Geographic Atrophy Drugs Market, by Disease Stage

  • 12.1. Advanced Stage
  • 12.2. Early Stage
  • 12.3. Intermediate Stage

13. Geographic Atrophy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Geographic Atrophy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Geographic Atrophy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Geographic Atrophy Drugs Market

17. China Geographic Atrophy Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alexion Pharmaceuticals, Inc.
  • 18.7. Amgen Inc.
  • 18.8. Apellis Pharmaceuticals, Inc.
  • 18.9. Astellas Pharma Inc.
  • 18.10. Biogen Inc.
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Bristol Myers Squibb Company
  • 18.13. Catalyst Biosciences, Inc.
  • 18.14. EyePoint Pharmaceuticals, Inc.
  • 18.15. Graybug Vision, Inc.
  • 18.16. Ionis Pharmaceuticals, Inc.
  • 18.17. IVERIC bio, Inc.
  • 18.18. Kodiak Sciences Inc.
  • 18.19. Merck & Co., Inc.
  • 18.20. Novartis AG
  • 18.21. Pfizer Inc.
  • 18.22. Regeneron Pharmaceuticals, Inc.
  • 18.23. Roche Holding AG
  • 18.24. Sanofi

LIST OF FIGURES

  • FIGURE 1. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MICROPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MICROPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY MICROPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TOPICAL FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TOPICAL FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TOPICAL FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SECONDARY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SECONDARY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TERTIARY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY TERTIARY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTERMEDIATE STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTERMEDIATE STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY INTERMEDIATE STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 157. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 184. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. NATO GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY SUSTAINED RELEASE SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA GEOGRAPHIC ATROPHY DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)